Public consultation / Recruiting CP
Marsha Greene & Zubin Master, 2018, Senior Policy Analyst, Peraton & Biomedical Ethics Research Program, Mayo Clinic, https://www.ndu.edu/Portals/59/Documents/Incoming/AY21%20Briefings/NDU%206070/CRISPR_Military.pdf?ver=2020-08-11-170728-347, " Ethical Issues of Using CRISPR Technologies for Research on Military Enhancement" Journal of Bioethical Inquiry (ermo/sms, Acc:6-8-2022)
We conclude with two points. First is to encourage public and stakeholder engagement on the ethics of using CRISPR in military enhancement technology. Currently, public debate on the use of CRISPR for germline and enhancement purposes indicates that many in the public display concern about somatic and germline enhancements (McCaughey et al. 2016; Pew Research Center 2016; STAT-Harvard T.H. Chan School of Public Health 2016; Gaskell et al. 2017; Scheufele et al. 2017). These studies capture the views of different populations and vary in how questions are worded thereby accounting for some of the differences in opinions. But no study has yet to investigate the views of stakeholders on the use of CRISPR for enhancement for the purpose of protecting soldiers. Public and stakeholder views may differ when considering the use of CRISPR technology for military enhancement. Engagement within DoD and the public will help DoD research ethicists and leadership understand public and stakeholder concerns and be able to manage ethical issues of research involving military personnel as the research is translated into human applications. To promote discourse, several deliberative strategies and research methods could be employed including town hall meetings, citizen juries, consensus conferences, polling, and focus groups among others (Abelson et al. 2003). Deliberation can focus on a range of ethical questions such as how to translate CRISPR gene technology for military applications, how best to handle research ethics issues including informed consent and risk analysis for first-in-human studies, and when and how to best inform the public to ensure transparency of gene editing research.
The second point is that DoD should consider several research ethics issues as this technology moves forward. Gene editing is clearly advancing and as gene modification becomes accepted in military research, several considerations need to be made to minimize risks and ensure service members are appropriately informed should they become research participants. This will include taking steps to reduce the group pressure that could be a by-product of military cohesiveness training and making improvements in the consent process such that service members understand the risks and purpose of these interventions. The military will likely be watching the first-in-human trials very closely while simultaneously exhausting all preclinical options in order to fully evaluate the risks of off-target effects. There will need to be some certainty from further validated studies prior to initiating any wide-scale use for military applications. Additionally, researchers and military leadership alike will need to be cognizant of the potential for CRISPR applications to be deployed in the military setting prior to approval of these interventions by the FDA. Prior to invoking the Interim Rule due to a bioterrorist threat, several considerations need to be weighed to ensure appropriate protections to front line military personnel. From the DoD perspective, ensuring that service members have the best available protection in a war zone is paramount. However, this creates many ethical issues regarding breach of individual rights and autonomy. At the same time, a consideration could be that these risks are built into enlisting and recruiting discussions so that service members understand clearly that this is a possibility under certain scenarios. While the President’s Council in 2003 felt that the risks of using gene editing for military enhancement were too high, it remains unclear given scientific advancements in gene editing whether similar conclusions would be made.